Xconomy

AUGUST 26, 2016

Mylan bumped up the price of the EpiPen 400 percent, presidential nominee Hillary Clinton responded with a tirade against drug price hikes, and—much like when Clinton railed against drug pricing last year—biotech indexes promptly plummeted more than 3 percent. It was the tweet heard around the biotech world, again.

Pricing 40

Pricing Thousand Oaks Startup Research 40

Xconomy

AUGUST 19, 2016

Everyone is waiting until 2017, when huge studies of the drugs’ ability to prevent heart attacks and strokes start to provide data. Data from the other three trials should come in late 2016 or early 2017.

Technical Review 40

Technical Review Patents .Net Study 40

Xconomy

AUGUST 12, 2016

The new company, expected to launch in 2017, will trade on the Nasdaq under the symbol “BIVV” when the split is complete. —This week’s gene therapy news: MIT Technology Review reported that Strimvelis, the gene therapy recently approved in Europe and given a $665,000 price tag, has a money-back guarantee if it doesn’t work.

Google 40

Google Technical Review News Research 40

Xconomy

JULY 19, 2019

In late 2017, a federal watchdog unit assigned a working group to keep an eye on cryptocurrencies such as Bitcoin, and to sound an alert if those alternate currencies showed signs of becoming a risk to the stability of the US financial system.

Pricing 89

Pricing Report Invest Venture Capital 89

Xconomy

MARCH 8, 2019

In early 2017, Scott Gottlieb was considered the most moderate of the potential candidates to head the Food and Drug Administration, which is the most powerful regulator of medical products in the world. It wasn’t a high bar to clear. Still, Gottlieb had spent time in the George W. His potential financial conflicts, combined.

Report 77

Report Product San Diego Pricing 77

Xconomy

MARCH 5, 2019

He leaves a record of health and medical regulation that was more active than critics who spoke out against his nomination in early 2017 might have expected. Two months after insisting on Twitter that he wasn’t going anywhere , Food and Drug Administration Commissioner Scott Gottlieb announced his resignation today.

News 87

News Course Activity San Diego 87

Xconomy

JULY 20, 2018

After nearly two years of all smoke, no fire around President Trump’s promise to curtail drug prices, there’s finally some glimmer of action. Pfizer said last week it would halt its price hikes, and Novartis and Merck took similar actions this week. Read more » Reprints | Share: UNDERWRITERS AND PARTNERS.

Pricing 57

Pricing San Diego Blogging 57

Xconomy

FEBRUARY 12, 2018

As president-elect, Donald Trump in January 2017 slammed drug companies for “getting away with murder” and said he supported Medicare negotiation. He vowed during last month’s State of the Union speech that drug prices “will come down.” The first is drug importation—bringing in cheaper products from.

Pricing 84

Pricing Product San Diego Company 84

Xconomy

JANUARY 5, 2018

Hopefully a lot less hatred, greed, stupidity, and angst than 2017. Two other big questions we raised immediately became topics of conversation this week, thanks to Spark Therapeutics, which set the price for its gene therapy—the first ever approved in the U.S.—at Welcome to the new year. What will it bring?

Pricing 55

Pricing News Develop Development 55

Xconomy

JANUARY 20, 2017

Here’s an excerpt of their Q&A: —What is your biggest healthcare-related fear for 2017? Alex Lash, our national biotech editor, traded e-mails with Bob Nelsen , co-founder and managing director at Arch Venture Partners. Nelsen is based in Seattle). Bob Nelsen Nelsen : Biggest fear is accidental.

Pricing 40

Pricing Networking Venture Capital San Diego 40

Xconomy

JANUARY 27, 2017

And a group of biotechs led by Jounce Therapeutics were the first to test the IPO market in 2017. A flurry of deals took place, headlined by Johnson & Johnson’s $30 billion gamble on Swiss firm Actelion. Meanwhile in Washington, President Donald Trump spent much of his first week signing executive orders on a variety of.

News 40

News Study Marketing Anthem 40

Both Sides of the Table

SEPTEMBER 17, 2017

I believe this use of cryptocurrency will develop and flourish long after the dust settles from the hype and crash of cryptocurrencies that we’re experiencing in 2017. Decentralized Internet — This is perhaps the most unsexy part of cryptocurrency but the one that most purists I follow on this topic are most excited about.

Course 280

Course Startup Framework Marketing 280

Xconomy

OCTOBER 28, 2016

Two “triple” combination regimens for CF , which are meant to expand the reach of its CF drugs, will begin Phase 2 trials by the end of the year, and two additional new CF drugs will start clinical testing in 2017. THIS WEEK IN DRUG PRICING…. —A coalition of investors pressed drug makers to justify price increases.

Pricing 40

Pricing Conference News Study 40

Xconomy

NOVEMBER 11, 2016

Drug company stocks got a boost with the defeat of Hillary Clinton, a vocal critic of drug prices. Will he take a softer stance on drug prices? But her near doubling of Trump (62 to 33 percent) didn’t translate into support for drug price controls. Now, the U.S. healthcare sector will try to figure out what it all means.

Patents 87

Patents Study Pricing IBM 87

Xconomy

DECEMBER 23, 2016

The biggest issues of 2016 are also the biggest questions of 2017: What do the Trump administration and Republican-led Congress have in store for federal health initiatives, laws, and agency budgets? Will government and public pressure force change on drug prices? Or will drug makers and.

Pricing 40

Pricing San Diego Blogging 40